Entity

Time filter

Source Type

Czech Republic

Background: The efficacy of anticancer therapy is regularly evaluated using the following indicators - objective response rate, progression free survival and overall survival. The change in the tumor burden extent is assessed by the cumulative change in the size of target tumor lesions using imaging methods where WHO and RECIST criteria are most frequently used. The main problem of these criteria is that they use different definitions of response rate evaluation. Generally, existing results of these evaluations do not confirm a direct correlation between the objective response rate and survival (progression free survival or overall survival). Another problem of these methods is that the results of the assessment do not correlate with the biological activity of tumor growth, since it is a static evaluation of clinical status. /Mm: This review article provides an overview of results related to new possibilities for evaluating the efficacy of anticancer therapy using the concept of depth of response and the concept of early tumor shrinkage in patients with metastatic colorectal cancer. Conclusion: The results of numerous post-hoc and exploratory analyses of clinical studies consistently suggest that early tumor shrinkage and depth of response are important variables in assessing the efficacy of systemic anticancer treatment. Source


Holubec L.,Biomedicinske centrum | Fiala O.,Biomedicinske centrum | Matejka V.M.,Biomedicinske centrum | Liska V.,Biomedicinske centrum | And 2 more authors.
Onkologie (Czech Republic) | Year: 2014

Colorectal cancer has the highest incidence rate in the Czech Republic and occupies one of the leading positions in incidence worldwide. Only patients with resectable distant metastases have hope for a cure. Prolongation of survival and improvement in the quality of life thus remain the main goal of cancer treatment. The possibilities of classic chemotherapy appear to be currently exhausted. Further prolongation of survival of patients with metastatic colorectal cancer (mCRC) has been provided by targeted biological therapy. It is crucial to find suitable predictive biomarkers that will allow identification of a target population of patients. The review article analyses the RAS mutation status with respect to the possible sequence of targeted biological therapy in patients with mCRC with regard to the new data presented at ASCO 2014. Source

Discover hidden collaborations